Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Sponsor: Replimune, Inc.
Where it's recruiting
Beverly Hills · La Jolla
Miami · Tampa
Baltimore
Buffalo · The Bronx
Philadelphia · Pittsburgh
Germantown · Knoxville
Houston
Source: ClinicalTrials.gov · NCT05733598 · last updated 2026-04-02